Drugs / CIK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02585908 | Dec 2019 → Dec 2021 | gastric cancer | Beijing Doing Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02585908 ↗ |
| Modality | Cell therapy | “CIK cells will be used against tumor cells.” NCT02585908 ↗ |